Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes

Diabetes Care

Volumn 40, Issue 11, 2017, Pages 1469-1478

  Carls, Ginger S ^a   Tuttle, Edward ^a   Tan, Ruo Ding ^a   Huynh, Johnny ^a   Yee, John ^b   Edelman, Steven V ^c,d,e   Polonsky, William H ^f,g  

^a ANALYSIS GROUP   (United States)

^b Research Triangle   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Taking Control of Your Diabetes   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Behavioral Diabetes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN;

ADULT; AGED; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; FOLLOW UP; MEDICATION COMPLIANCE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 85033228169     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2725     Document Type: Conference Paper

References (49)

1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U. S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624
2. Carls G, Huynh J, Tuttle E, Edelman S. Achievement of glycated hemoglobin goals in the U. S. remains unchanged through 2014. Presented at the 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, at the Ernest N. Morial Convention Center, New Orleans, LA
3. U. S. Food and Drug Administration. FDAapproved diabetes medicines [article online]. Available fromhttps://www. fda. gov/ForPatients/ Illness/Diabetes/ucm408682. htm. Accessed 18 September 2017
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
5. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
6. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010;29:1818-1825
7. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply" Lancet 2005;365:82-93
8. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224
9. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287-1305
10. Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study. Adv Ther 2015;32: 341-355
11. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
12. Vilsbøll T, ChristensenM, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists onweight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
13. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378-388
14. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-47
15. Centers for Medicare & Medicaid Services (CMS). Medicare 2015 Part C & D Star Rating Technical Notes [Internet], 2015. Available from http://cdn5. medicarehelp. org/wp-content/uploads/ 2014/10/2015-Tech-Notes-2014-10-03. pdf. Accessed 3 March 2016
16. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-1841
17. National Quality Forum (Ed.). National Quality Forum (NQF)-Endorsed Measures for Endocrine Conditions, 2013-2015: Final Report. Technical Report. Washington, DC, National Quality Forum, 2015
18. Toh S, Manson JE. An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease. Stat Biosci 2013;5: 10. 1007/s12561-012-9073-6
19. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallelgroup, open-label trial. Lancet 2010;375:1447-1456
20. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
21. SinghalM, Nguyen H, SchauerhamerM, Unni S, Cobden D, McAdam-Mark C. Effect of daily or weekly GLP-1 receptor agonists on glycemic control in insulinnäve patients with poorly controlled type 2 diabetes: A real-world study. Poster presented at the ISPOR 20th Annual International Meeting, 16-20 May 2015, at the Philadelphia Marriott Downtown, Philadelphia, PA
22. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk ofmortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
23. Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin 2013;29:1275-1286
24. Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetesmellitus in challenging patient groups. Adv Ther 2013;30:1067-1085
25. MarreM, ShawJ, BrändleM, et al.; LEAD-1 SU study group. Liraglutide, a once-daily humanGLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
26. DiamantM, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 2010;375:2234-2243
27. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-1310
28. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373: 473-481
29. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 200932:1224-1230
30. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
31. DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
32. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168
33. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled onmetformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-1631
34. Manan MM, Husin AR, Alkhoshaiban AS, Al-Worafi YM, Ming LC. Interplay between oral hypoglycemic medication adherence and quality of life among elderly type 2 diabetes mellitus patients. J Clin Diagn Res 2014;8:JC05-JC09
35. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805
36. Zhu VJ, Tu W, Marrero DG, Rosenman MB, Overhage JM. Race and medication adherence and glycemic control: findings from an operational health information exchange. AMIA Annu Symp Proc 2011;2011:1649-1657
37. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: A retrospective cohort study. Adv Ther 2014;31:986-999
38. Li Q, Chitnis A, Hammer M, Langer J. Realworld clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther 2014; 5:579-590
39. DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther 2014;31: 202-216
40. Thayer S, Chow W, Korrer S, Aguilar R. Realworld evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087-1096
41. Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia 2014;57: 1304-1307
42. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag 2005;1:189-199
43. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: A literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-434
44. Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes [published correction appears in Clin Ther 2015;37:1870]. Clin Ther 2003;25:2307-2335; discussion 2306
45. Shi L, HodgesM, Yurgin N, Boye KS. Impact of dose frequency on compliance and health outcomes: A literature review (1966-2006). Expert Rev Pharmacoecon Outcomes Res 2007;7:187-202
46. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014;5:e45
47. Haynes RB, Ackloo E, SahotaN, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008
48. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014
49. Bodenheimer T. Coordinating care-A perilous journey through the health care system. N Engl J Med 2008;358:1064-1071